Shares of ResMed Inc. shed 8.33% to $236.18 Friday, on what proved to be an all-around dismal trading session for the ...

Medical device company ResMed (NYSE:RMD) announced in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed (RMD – Research Report), with a price target of ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

RBC Capital raised the firm’s price target on ResMed (RMD) to $247 from $238 and keeps a Sector Perform rating on the shares. The company ...

Although RMD has re-rated from its share price low of around $21.50 in October 2023, it has only just surpassed its all-time ...

ResMed boss Mick Farrell says the new Trump administration could be a tailwind for the company, likely locking in a ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

尽管业绩超预期,ResMed股价在常规交易时段大幅下跌8.33%。这一下跌可能归因于更广泛的市场趋势或投资者对未来增长前景的担忧。股价在盘后交易中略有反弹,上涨0.28%。

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

周五，Oppenheimer分析师在ResMed（纽约证券交易所代码：RMD）公布2025财年第二季度财务业绩后，维持了对该公司的"表现"评级。ResMed报告收入同比增长10%，达到12.82亿美元，超过了Oppenheimer和市场预期的12.58亿美元和12.67亿美元。每股收益 (EPS)也超出预期，为2.34美元，高于预期的2.20美元和2.23美元。根据 InvestingPro 数据 ...